Leap Therapeutics, Inc.
LPTX
$0.28
-$0.0122-4.18%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 3.01M | 2.94M | 3.37M | 3.53M | 3.14M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 16.13M | 18.35M | 21.00M | 14.58M | 14.84M |
Operating Income | -16.13M | -18.35M | -21.00M | -14.58M | -14.84M |
Income Before Tax | -15.55M | -17.47M | -20.36M | -13.82M | -12.47M |
Income Tax Expenses | -123.00K | 708.00K | -- | -- | -- |
Earnings from Continuing Operations | -15.43M | -18.18M | -20.36M | -13.82M | -12.47M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -15.43M | -18.18M | -20.36M | -13.82M | -12.47M |
EBIT | -16.13M | -18.35M | -21.00M | -14.58M | -14.84M |
EBITDA | -16.13M | -18.35M | -21.00M | -14.57M | -14.84M |
EPS Basic | -0.38 | -0.44 | -0.52 | -0.51 | -0.46 |
Normalized Basic EPS | -0.47 | -0.26 | -0.32 | -0.32 | -0.29 |
EPS Diluted | -0.38 | -0.44 | -0.52 | -0.51 | -0.46 |
Normalized Diluted EPS | -0.47 | -0.26 | -0.32 | -0.32 | -0.29 |
Average Basic Shares Outstanding | 41.25M | 41.21M | 39.12M | 27.01M | 26.99M |
Average Diluted Shares Outstanding | 41.25M | 41.21M | 39.12M | 27.01M | 26.99M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |